Found: 8
Select item for more details and to access through your institution.
Quality of life in patients with β‐thalassemia: A prospective study of transfusion‐dependent and non‐transfusion‐dependent patients in Greece, Italy, Lebanon, and Thailand.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 10, p. E261, doi. 10.1002/ajh.25584
- By:
- Publication type:
- Article
Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO<sup>©</sup>).
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 2, p. 177, doi. 10.1002/ajh.25344
- By:
- Publication type:
- Article
Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO<sup>©</sup>).
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 2, p. 171, doi. 10.1002/ajh.25343
- By:
- Publication type:
- Article
Sotatercept in patients with osteolytic lesions of multiple myeloma.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 6, p. 814, doi. 10.1111/bjh.12835
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 1, p. 52, doi. 10.1002/jcph.1696
- By:
- Publication type:
- Article
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 7, p. 395, doi. 10.1002/psp4.12521
- By:
- Publication type:
- Article
Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 11, p. 1121, doi. 10.1002/jcph.160
- By:
- Publication type:
- Article